Colin S Osborne

Summary

Affiliation: Novartis Institutes for BioMedical Research

Publications

  1. pmc In vitro analysis of the ability of Trichophyton rubrum to become resistant to terbinafine
    Colin S Osborne
    Novartis Research Institute, 1235 Vienna, Austria
    Antimicrob Agents Chemother 47:3634-6. 2003
  2. ncbi request reprint Antifungal drug response in an in vitro model of dermatophyte nail infection
    C S Osborne
    Infectious Diseases Department, Novartis Research Institute, Vienna, Austria
    Med Mycol 42:159-63. 2004
  3. pmc In vivo characterization of the peptide deformylase inhibitor LBM415 in murine infection models
    Colin S Osborne
    Infectious Diseases, Novartis Institutes for BioMedical Research, Inc, Cambridge, MA 02139, USA
    Antimicrob Agents Chemother 53:3777-81. 2009
  4. pmc Amino acid substitution in Trichophyton rubrum squalene epoxidase associated with resistance to terbinafine
    Colin S Osborne
    Infectious Diseases, Novartis Institutes for BioMedical Research, Vienna, Austria
    Antimicrob Agents Chemother 49:2840-4. 2005
  5. pmc Biological, biochemical, and molecular characterization of a new clinical Trichophyton rubrum isolate resistant to terbinafine
    Colin S Osborne
    Infectious Diseases, Novartis Institutes for BioMedical Research, Inc, Cambridge, MA 02139, USA
    Antimicrob Agents Chemother 50:2234-6. 2006

Collaborators

Detail Information

Publications5

  1. pmc In vitro analysis of the ability of Trichophyton rubrum to become resistant to terbinafine
    Colin S Osborne
    Novartis Research Institute, 1235 Vienna, Austria
    Antimicrob Agents Chemother 47:3634-6. 2003
    ..Results demonstrated that naturally occurring mutants are rare and that T. rubrum appears to have little capacity to develop resistance to terbinafine even after prolonged exposure...
  2. ncbi request reprint Antifungal drug response in an in vitro model of dermatophyte nail infection
    C S Osborne
    Infectious Diseases Department, Novartis Research Institute, Vienna, Austria
    Med Mycol 42:159-63. 2004
    ..rubrum after 4 weeks incubation in this model. Invasive mycelial growth on nail appears to protect T. rubrum from the cidal action of systemic drugs, thus providing a rationale for the long treatment periods in onychomycosis...
  3. pmc In vivo characterization of the peptide deformylase inhibitor LBM415 in murine infection models
    Colin S Osborne
    Infectious Diseases, Novartis Institutes for BioMedical Research, Inc, Cambridge, MA 02139, USA
    Antimicrob Agents Chemother 53:3777-81. 2009
    ..Results suggest the potential of peptide deformylase inhibitors as a novel class of therapeutic agents against antibiotic-resistant pathogens...
  4. pmc Amino acid substitution in Trichophyton rubrum squalene epoxidase associated with resistance to terbinafine
    Colin S Osborne
    Infectious Diseases, Novartis Institutes for BioMedical Research, Vienna, Austria
    Antimicrob Agents Chemother 49:2840-4. 2005
    ..Terbinafine resistance in these T. rubrum clinical isolates appears to be due to a single amino acid substitution in SE...
  5. pmc Biological, biochemical, and molecular characterization of a new clinical Trichophyton rubrum isolate resistant to terbinafine
    Colin S Osborne
    Infectious Diseases, Novartis Institutes for BioMedical Research, Inc, Cambridge, MA 02139, USA
    Antimicrob Agents Chemother 50:2234-6. 2006
    ..Resistance to terbinafine in this strain is caused by a missense mutation in the squalene epoxidase gene leading to the amino acid substitution F397L...